University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

San Raffaele Hospital is one of the top centers of Gruppo San Donato (Italy’s largest hospital group, treating over 4.7 million patients yearly). San Raffaele University & Research Hospital is an institute that incorporates clinical, research and university activities altogether, while being internationally recognized for its specialization in some of the most complex pathologies. The hospital is a multi-specialty center with more than 50 clinical specialties covered and over 1300 beds, which is accredited by the Italian National Health System to provide treatment to both public and private, national and international patients. In 2016, the San Raffaele Hospital performed nearly 51,000 patient admissions, 67,700 emergency room interventions and delivered over 7 million healthcare services, including outpatient appointments and diagnostic exams. It is considered to be the most famous hospital in the country and among the most reputable medical centers in Europe.

Fondazione Telethon, a subsidiary of Founders Combined Charity Income Common Investment Fund, is a company headquartered in Rome, Italy, that operates as a healthcare charity.\nThe company says this about itself: Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than € 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments.

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Chromatin, Inc. provides seed and feedstock products for traditional agriculture and bio-industrial processes. The firm markets seed products under its Sorghum Partners brand, primarily the grain sorghum and forage sorghum seed types. It also delivers sorghum products for companies seeking renewable feedstock. Its service areas encompass supplying seed, contracting growers, providing agronomic support, and overseeing harvest and delivery of feedstock in the form and specifications required by bio-processors. The company was founded by Kevin Keith, Daphne Preuss and Gregory Paul Copenhaver in 2001 and is headquartered in Chicago, IL.

SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.

Shenzhen Yikang Biotechnology Co., Ltd., established on 2017-06-21, Business scope includes general business items:Research and development of biotechnology;Information Consulting;Operating import and export business;Invest in business(There is a project to declare separately).,The licensing program is:Research and development of biological products,Sales;R&D of medical devices,Sales;Research and development of biological in vitro diagnostic reagents,Production,Sales;IISales of medical-like cross molecular products.

Polish Stem Cell Bank (PBKM) is the largest stem cell bank in Poland and Europe. We store biological material from customers from dozens of European countries. We also have the most experience in transferring material for transplantation. Our mission is to provide access to innovative treatment from harvested stem cells to save the life and health of your child or other family members. Our primary goal is to extract and store stem cells from cord, placental and umbilical cord. The continuous implementation of this goal is confirmed by extensive, documented experience in the transfer of stem cells for transplantation in Poland and abroad. At every stage of our business, we strive to meet the highest technological and ethical standards to give our customers the confidence to choose a Partner they can trust for years to come. At the Polish Stem Cell Bank, we believe that being a responsible company is right not only for the development of our business, but above all for parents who give us in storage valuable material collected during childbirth.

The Kyungpook National University Hospital is located in Daegu, South Korea. It was derived from the DaeGuDongIn Hospital which had opened in 1907. It has played as centered hospital of Gyeongsangbuk-do. As 1952 Kyungpook National University is established, it is following to the Kyungpook National University Hospitals. It is known to Korean as important general hospitals.

SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA.

Yangling Keyuan Clone Co., Ltd., established on 2001-02-18, The business scope includes fine-bred beef cattle,the cow,sheep and its embryos,frozen semen,Production and sales of biological products;Embryo Engineering Technical Services;Technology Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sichuan Jinyu Medical Laboratory Co., Ltd., established on 2010-03-03, Business scope includes licensed projects:medical service;Inspection and testing service;Class III medical device business;road freight transport(Does not contain dangerous goods);Class III Medical Device Leasing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class II Medical Devices;Class II Medical Device Leasing;Sales of Class I Medical Devices;Class I Medical Device Leasing;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Development of Human Gene Diagnosis and Therapy Technology;Domestic Freight Forwarding;total mass4.5Road freight transport of ordinary freight vehicles of 1 ton or less(Except network freight and dangerous goods);General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Labor service(Does not include labor dispatch);software development;Information Technology Consulting Services;Information system integration service.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)